Novartis loses global development head to Gates Foundation
pharmafile | September 14, 2011 | News story | Research and Development | Bill and Melinda Gates Foundation, Novartis, appointment
Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill and Melinda Gates Foundation.
He will remain with Novartis until 1 December, after which he will take up the role of executive director of the Foundation’s Global Health Program.
At Novartis Mundel’s responsibilities included overseeing the development of drug candidates provided by the Novartis Institutes for BioMedical Research (NIBR) or the company’s licensing partners.
Prior to joining Novartis, he worked for Warner Lambert and Pfizer in senior clinical development roles, including director in central nervous system clinical development and as head of experimental Medicine, respectively.
Novartis said it would name Mundel’s successor shortly.
Dominic Tyer
Related Content
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …